Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    An Exploratory Study of the Safety and Efficacy of Prophylactic Immunomodulatory Treatment in Myozyme®-Naive, CRIM(-) Patients With Infantile-onset Pompe Disease

    Summary
    EudraCT number
    2015-000584-14
    Trial protocol
    Outside EU/EEA  
    Global end of trial date
    27 Mar 2013

    Results information
    Results version number
    v1(current)
    This version publication date
    23 May 2016
    First version publication date
    25 Jun 2015
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    AGLU03807, MSC12862
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT00701129
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Genzyme Corporation
    Sponsor organisation address
    500 Kendall Street, Cambridge, United States, 02142
    Public contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Scientific contact
    Trial Transparency Team, Sanofi aventis recherche & développement, Contact-US@sanofi.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    30 Apr 2013
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    27 Mar 2013
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The objectives were to assess the efficacy of a prophylactic immunomodulatory regimen given prior to first treatment with alglucosidase alfa, as assessed by anti-recombinant human acid alpha-glucosidase (anti-rhGAA) antibody titers, and antibodies that inhibit the activity and/or uptake of alglucosidase alfa; to evaluate the clinical benefit as measured by overall survival, ventilator-free survival, left ventricular mass index (LVMI), gross motor function and development, disability index and the incidence of adverse events (AEs), serious adverse events (SAEs), and clinical laboratory abnormalities.
    Protection of trial subjects
    The study was conducted by investigators experienced in the treatment of pediatric subjects. The parent(s) or guardian(s) as well as the children were fully informed of all pertinent aspects of the clinical trial as well as the possibility to discontinue at any time. In addition to the consent form for the parent(s)/guardian(s), an assent form in child-appropriate language was provided and explained to the child. Repeated invasive procedures were minimized. The number of blood samples as well as the amount of blood drawn were adjusted according to age and weight. A topical anesthesia may have been used to minimize distress and discomfort.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Oct 2009
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United States: 4
    Worldwide total number of subjects
    4
    EEA total number of subjects
    0
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    4
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    0
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    The study was conducted at 2 centres in the United States of America between October 01, 2009 and March 27, 2013.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Alglucosidase Alfa
    Arm description
    Alglucosidase alfa was given every other week (qow) or every week (qw) beginning from Day 0 to a minimum of 18 months or if the subject was less than (<) 6 months of age at the time of enrollment, until the subject was 2 years of age, along with methotrexate for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.
    Arm type
    Experimental

    Investigational medicinal product name
    Alglucosidase Alfa
    Investigational medicinal product code
    Other name
    Myozyme®
    Pharmaceutical forms
    Powder and solvent for concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    20 mg/kg

    Investigational medicinal product name
    Rituximab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate for solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    375 mg/m^2

    Investigational medicinal product name
    Methotrexate
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    0.4 mg/kg

    Number of subjects in period 1
    Alglucosidase Alfa
    Started
    4
    Full Analysis Set (FAS)
    4
    Completed
    2
    Not completed
    2
         Death
    2

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Alglucosidase Alfa
    Reporting group description
    Alglucosidase alfa was given every other week (qow) or every week (qw) beginning from Day 0 to a minimum of 18 months or if the subject was less than (<) 6 months of age at the time of enrollment, until the subject was 2 years of age, along with methotrexate for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.

    Reporting group values
    Alglucosidase Alfa Total
    Number of subjects
    4 4
    Age categorical
    Units: Subjects
        Less Than or Equal to (=<) 6 Months
    2 2
        Greater Than (>) 6 Months
    2 2
    Gender categorical
    Units: Subjects
        Female
    3 3
        Male
    1 1
    Race
    Units: Subjects
        Black
    2 2
        White
    1 1
        White, Black
    1 1
    Ethnicity
    Units: Subjects
        Hispanic
    2 2
        Non Hispanic
    2 2
    Number of Subjects With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G
    As all subjects were treatment naïve, it was expected that no subject would be Anti-rhGAA immunoglobulin G (IgG) antibody positive at baseline.
    Units: Subjects
        Negative
    4 4
        Positive
    0 0
    Number of Subjects With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score
    LVM Z-Score was assessed by echocardiography (ECHO). LVM Z-Score: an indicator of degree of standard deviations from mean in a normal distribution. Negative values indicate a smaller LVM than mean and values higher than 0 indicate a larger LVM than mean. Normal range is -2 to 2; values <-2 or >2 indicate abnormal score.
    Units: Subjects
        Normal
    0 0
        Abnormal
    4 4
    Number of Subjects With Normal/Abnormal LVM Index
    LVM Index was assessed by echocardiography (ECHO). LVM index: an index value derived by normalizing LVM by body surface area. LVM index provides evidence of cardiomyopathy. LVM index values <65 gram per square meter (g/m^2) were considered as normal and LVM index values >=65 g/m^2 were considered as abnormal.
    Units: Subjects
        Normal
    0 0
        Abnormal
    4 4
    Number of Subjects With Ventilator Use
    Units: Subjects
        Yes
    3 3
        No
    1 1
    Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88)
    GMFM-88:an 88-item measure to detect gross motor function; consists of 5 categories: lying and rolling; sitting; crawling and kneeling; standing; walking, running and jumping. Each item is scored on a 4-point Likert scale(0=cannot do; 1=initiates [<10% of the task]; 2=partially completes [10% to <100% of the task]; 3=task completion). Score for each dimension is expressed as a percentage of maximum score for that dimension. Total score=sum of percentage scores for each dimension divided by number of dimensions. Total score range: 0% to 100%, where higher scores indicate better motor functions.
    Units: percentage of maximum total score
        median (full range (min-max))
    5.1 (0.39 to 7.49) -
    Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS)
    AIMS:58-item in 4 subscales: prone; supine; sitting; and standing. Each item is scored as observed/not observed. Item in observed range create a motor window. Subscale scores are calculated by giving child 1 point for observed items within motor window in addition to being given 1 point for all less mature items before motor window. AIMS total score=sum of scores for 58 items, range: 0-58,higher score=more mature motor development. Score was then compared with age-equivalent peers from normative sample and equivalence level age (in months) is reported. Here, number of subjects analyzed = 3.
    Units: months
        median (full range (min-max))
    0 (0 to 1.37) -
    Disability Index-Pompe Pediatric Evaluation of Disability Inventory-Functional Skills:Mobility (n=4)
    All items of original Pompe Pediatric Evaluation of Disability Inventory (Pompe –PEDI) (197 functional skill in 3 domains:self-care;mobility;social function) and additional items in functional skills,mobility was self-care . Each domain consists of 2 subdomains: functional skill performance, caregiver assistance scale. Norm-based scoring was developed for additional items, and scoring for PEDI have been adjusted to reflect additional normative data collected for Pompe PEDI. Total score range for each domain (mean of subdomains) and subdomain=0-100;higher score=high capability.
    Units: units on a scale
        median (full range (min-max))
    4.5 (0 to 18.4) -
    Disability Index-Pompe PEDI-Functional Skills: SelfCare (n=4)
    Units: units on a scale
        median (full range (min-max))
    14.4 (4.9 to 16.1) -
    Disability Index-Pompe PEDI-Functional Skills: Social Function (n=1)
    Units: units on a scale
        median (full range (min-max))
    10.5 (10.5 to 10.5) -
    Disability Index-Pompe PEDI-Caregiver Assistance: Mobility (n=2)
    Units: units: units on a scale
        median (full range (min-max))
    0 (0 to 0) -
    Disability Index-Pompe PEDI-Caregiver Assistance: Self-Care (n=2)
    Units: units: units on a scale
        median (full range (min-max))
    0 (0 to 0) -
    Disability Index-Pompe PEDI-Caregiver Assistance: Social Function (n=2)
    Units: units: units on a scale
        median (full range (min-max))
    0 (0 to 0) -

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Alglucosidase Alfa
    Reporting group description
    Alglucosidase alfa was given every other week (qow) or every week (qw) beginning from Day 0 to a minimum of 18 months or if the subject was less than (<) 6 months of age at the time of enrollment, until the subject was 2 years of age, along with methotrexate for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.

    Primary: Change From Baseline in Number of Subjects With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study

    Close Top of page
    End point title
    Change From Baseline in Number of Subjects With Anti-Recombinant Human Acid Alfa-glucosidase (Anti-rhGAA) Immunoglobulin G (IgG) Antibody at End of Study [1]
    End point description
    Serum samples from subjects were analyzed for the presence of anti-rhGAA IgG antibodies. End of study (EOS) refers to the last post baseline observation during study period (up to Week 79). FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    Baseline, End of Study (up to Week 79 or early termination)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    4
    Units: subjects
        Baseline - Negative; EOS - Positive
    2
        Baseline - Negative; EOS - Negative
    2
    No statistical analyses for this end point

    Primary: Number of Subjects With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of Study

    Close Top of page
    End point title
    Number of Subjects With Recombinant Human Acid Alfa-glucosidase (rhGAA) Inhibitory Antibody at End of Study [2]
    End point description
    Subjects with positive anti-rhGAA IgG antibody were assessed for the presence of inhibitory antibodies (inhibition of enzyme activity and inhibition of enzyme uptake). Enzyme-linked immunosorbent assay (ELISA) was used to measure inhibition of rhGAA enzymatic activity in vitro and a cell-based assay was used to measure the inhibition of the uptake of rhGAA in normal fibroblast cells by flow cytometry. FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa. Here, number of subjects analyzed = subjects with positive anti-rhGAA IgG antibody.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    2
    Units: subjects
        Inhibition of Enzyme Activity
    0
        Inhibition of Enzyme Uptake
    0
    No statistical analyses for this end point

    Primary: Number of Subjects Who Survived at End of Study

    Close Top of page
    End point title
    Number of Subjects Who Survived at End of Study [3]
    End point description
    FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    Baseline up to End of study (Week 79)
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    4
    Units: subjects
    2
    No statistical analyses for this end point

    Primary: Number of Subjects With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of Study

    Close Top of page
    End point title
    Number of Subjects With Normal/Abnormal Left Ventricular Mass (LVM) Z-Score and LVM Index at End of Study [4]
    End point description
    LVM Z-score and LVM index were assessed by ECHO. LVM Z-Score provides an indicator of degree of standard deviations from the mean in a normal distribution. Negative values indicate a smaller LVM than mean and values higher than 0 indicate a larger LVM than the mean. The normal range for LVM Z-Score is -2 to 2. Values <-2 or >2 indicate abnormal LVM Z-Score. LVM index is an index value derived by normalizing LVM by body surface area. LVM index provides evidence of cardiomyopathy. LVM index values <65 gram per meter^2 (g/m^2) were considered as normal and LVM index values >=65 g/m^2 were considered as abnormal. End of study refers to the last post baseline observation during study period (up to Week 79). FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79 or early termination)
    Notes
    [4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    4
    Units: subjects
        LVM Z-score: Normal
    3
        LVM Z-score: Abnormal
    1
        LVM index: Normal
    2
        LVM index: Abnormal
    2
    No statistical analyses for this end point

    Primary: Number of Subjects With Ventilator Use at End of Study

    Close Top of page
    End point title
    Number of Subjects With Ventilator Use at End of Study [5]
    End point description
    Number of subjects who had ventilator support at end of study was reported. End of study refers to the last post baseline observation during study period (up to Week 79). FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79 or early termination)
    Notes
    [5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    4
    Units: subjects
        Yes
    3
        No
    1
    No statistical analyses for this end point

    Primary: Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of Study

    Close Top of page
    End point title
    Gross Motor Disability Assessed by Gross Motor Function Measure-88 (GMFM-88) at End of Study [6]
    End point description
    GMFM-88 is an 88-item measure to detect gross motor function. Consist of 5 categories: lying and rolling; sitting; crawling and kneeling; standing; walking, running and jumping. Each item is scored on a 4-point Likert scale (0=cannot do; 1=initiates [<10% of the task]; 2=partially completes [10% to <100% of the task]; 3=task completion). Score for each dimension is expressed as a percentage of the maximum score for that dimension. Total score is obtained by adding percentage scores for each dimension and dividing sum by total number of dimensions. Total score ranges from 0% -100%, where higher scores indicate better motor functions. Total score of <7.5% demonstrates gross motor disability. End of study refers to last post baseline observation during study period (up to Week 79). FAS population included all enrolled subjects who signed informed consent and received at least 1 dose of alglucosidase alfa. Here, numbers of subjects analyzed = subjects with end of study GMFM-88 assessment.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79 or early termination)
    Notes
    [6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    3
    Units: percentage of maximum total score
        median (full range (min-max))
    8.24 (6.76 to 89.8)
    No statistical analyses for this end point

    Primary: Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of Study

    Close Top of page
    End point title
    Motor Development Status Assessed by Alberta Infantile Motor Scale (AIMS) at End of Study [7]
    End point description
    AIMS: 58-item reliable and valid measure of motor development for infants at risk for motor delay. It assesses infant movement in 4 positions (subscales): prone (reciprocal crawling);supine (moving hands to feet);sitting (sitting with arm support);standing (pulls to stand). For each subscale, items were scored as "observed" or "not observed". Item in observed range create motor window. Subscale scores are calculated by giving the child credit (1 point) for observed items within motor window in addition to being given credit (1 point) for all of less mature items before motor window. Total score was calculated by summing scores for 58 items (range: 0-58). Higher score=more mature motor development. Score was then compared with age-equivalent peers from normative sample and equivalence level age (months) is reported. End of study: last post baseline observation during study period (up to Week 79). FAS population. Numbers of subjects analyzed = subjects with end of study AIMS assessment.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79 or early termination)
    Notes
    [7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    3
    Units: months
        median (full range (min-max))
    1.09 (1 to 14.5)
    No statistical analyses for this end point

    Primary: Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of Study

    Close Top of page
    End point title
    Disability Index Assessed by the Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) at End of Study [8]
    End point description
    Pompe PEDI is disease specific version to assess functional capabilities and performance in children with Pompe (2 months-adolescence). It consists of (197 functional skill in 3 domains: self-care; mobility; and social function) and additional items in functional skills, mobility and self-care were clinically relevant functional. Each domain consisted of 2 subdomains: functional skill performance and caregiver assistance scale. Norm-based scoring was for additional items, and scoring algorithms for PEDI have been adjusted to reflect additional normative data collected for Pompe PEDI. Total score range for each domain (mean of subdomains) and subdomain ranges (0-100), where higher score indicates high capability. End of study was last post baseline observation during study period (up to Week 79). FAS population. Here, number of subject analyzed = number of subjects with end of study Pompe PEDI assessment and n = number of subjects with end of study assessment of specified category.
    End point type
    Primary
    End point timeframe
    End of study (up to Week 79 or early termination)
    Notes
    [8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: As the analysis was descriptive, no statistical analysis is provided.
    End point values
    Alglucosidase Alfa
    Number of subjects analysed
    3
    Units: units on a scale
    median (full range (min-max))
        Functional Skills: Mobility Score (n=3)
    25.1 (23.2 to 56)
        Functional Skills: Self-Care Score (n=3)
    39.3 (37 to 55.2)
        Functional Skills: Social Function Score (n=3)
    46.2 (40.4 to 46.8)
        Caregiver Assistance: Mobility Score (n=3)
    20.3 (20.3 to 31.9)
        Caregiver Assistance: Self-Care Score (n=2)
    28.7 (20.1 to 37.2)
        Caregiver Assistance: Social Function Score (n=3)
    48.5 (20.4 to 53.1)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    First dose of study drug up to end of study (up to Week 79)
    Adverse event reporting additional description
    In the event a single subject has experienced both serious and non-serious form of the same adverse event (AE), subject has been included in numerator of both AE tables. Analysis was performed on the safety population: all subjects who received at least 1 dose of alglucosidase alfa. AEs are listed independent of relationship to treatment.
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    15.1
    Reporting groups
    Reporting group title
    Alglucosidase Alfa
    Reporting group description
    Alglucosidase alfa was given every other week (qow) or every week (qw) beginning from Day 0 to a minimum of 18 months or if the subject was less than (<) 6 months of age at the time of enrollment, until the subject was 2 years of age, along with methotrexate for 3 consecutive days qow beginning from Day 0 to Week 6 (9 doses) and rituximab qw beginning from Day -1 to Week 4 (4 doses) as per local prescribing information. An additional 4-week cycle of rituximab (up to 4 additional doses) and 6-week cycle of methotrexate (up to 9 additional doses) may have been administered within the first 6 months of the study as per local prescribing information.

    Serious adverse events
    Alglucosidase Alfa
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 4 (75.00%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    Investigations
    Pulse Absent
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Injury, poisoning and procedural complications
    Feeding Tube Complication
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Torus Fracture
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vascular disorders
    Vena Cava Thrombosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Arrhythmia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Bradycardia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac Arrest
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Cardiopulmonary Failure
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    General disorders and administration site conditions
    Disease Progression
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pyrexia
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences causally related to treatment / all
    0 / 3
         deaths causally related to treatment / all
    0 / 0
    Ear and labyrinth disorders
    Tympanic Membrane Disorder
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Apnoea
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Dyspnoea
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Laryngeal Stenosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Hypoxia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Respiratory Distress
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Musculoskeletal and connective tissue disorders
    Muscle Contracture
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Tracheitis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pneumonia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Serratia Sepsis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Clostridium Difficile Colitis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 5
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Fluid Imbalance
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Alglucosidase Alfa
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    4 / 4 (100.00%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Fibroma
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Vascular disorders
    Vena Cava Thrombosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Flushing
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Hypotension
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Pallor
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Surgical and medical procedures
    Post Procedural Drainage
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Gastrointestinal Tube Removal
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    General disorders and administration site conditions
    Catheter Site Discharge
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Catheter Site Rash
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Device Occlusion
         subjects affected / exposed
    3 / 4 (75.00%)
         occurrences all number
    6
    Catheter Site Pruritus
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Face Oedema
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Device Dislocation
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Catheter Site Erythema
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Catheter Site Erosion
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Catheter Site Related Reaction
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Fatigue
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Intentional Medical Device Removal By Subject
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    7
    Medical Device Complication
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Oedema Peripheral
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Pyrexia
         subjects affected / exposed
    4 / 4 (100.00%)
         occurrences all number
    16
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    3
    Bronchospasm
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Bronchial Secretion Retention
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Aspiration
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Acute Respiratory Failure
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Rhinitis Allergic
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Atelectasis
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Respiratory Distress
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Pneumothorax
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Pneumonia Aspiration
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Diaphragm Muscle Weakness
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Increased Bronchial Secretion
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Diaphragmatic Disorder
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Dyspnoea
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Laryngeal Stenosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Rhinorrhoea
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    6
    Wheezing
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    5
    Tachypnoea
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Psychiatric disorders
    Agitation
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    3
    Investigations
    Blood Culture Positive
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Creatine Phosphokinase Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Creatine Phosphokinase Mb Increased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Alanine Aminotransferase Increased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Band Neutrophil Percentage Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    4
    Antibiotic Resistant Staphylococcus Test Positive
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Chloride Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Clostridium Test Positive
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    3
    Body Temperature Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Sodium Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Pressure Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Immunoglobulin G Increased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Blood Potassium Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Lactate Dehydrogenase Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Iron Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood Potassium Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Occult Blood Positive
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Neutrophil Percentage Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Neutrophil Count Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Eosinophil Percentage Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Lymphocyte Percentage Decreased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Heart Rate Irregular
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Heart Rate Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Moraxella Test Positive
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Weight Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Urine Output Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Urinary Hexose Tetrasaccharide Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Oxygen Saturation Decreased
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    6
    Specific Gravity Urine Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Respiratory Rate Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Respiratory Rate Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Protein Total Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Reticulocyte Percentage Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    White Blood Cell Count Decreased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    White Blood Cell Count Increased
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Injury, poisoning and procedural complications
    Spinal Compression Fracture
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Procedural Site Reaction
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Procedural Pain
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Overdose
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Lip Injury
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Laceration
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Burns Second Degree
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Medication Error
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Torus Fracture
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Cardiac disorders
    Bradycardia
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Extrasystoles
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Cyanosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Tachycardia
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Nervous system disorders
    Clonus
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Tremor
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Lymphadenopathy
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Anaemia
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    4
    Ear and labyrinth disorders
    Tympanic Membrane Disorder
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Eye disorders
    Eyelid Ptosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Conjunctivitis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Periorbital Oedema
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Gastrointestinal disorders
    Diarrhoea
         subjects affected / exposed
    3 / 4 (75.00%)
         occurrences all number
    10
    Anorectal Disorder
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Anal Sphincter Atony
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Constipation
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    4
    Retching
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    4
    Duodenogastric Reflux
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Flatulence
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Gastritis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Haematemesis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Haematochezia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Teething
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Vomiting
         subjects affected / exposed
    3 / 4 (75.00%)
         occurrences all number
    6
    Skin and subcutaneous tissue disorders
    Erythema
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Excessive Granulation Tissue
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Drug Eruption
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Eczema
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Dermatitis Contact
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Dermatitis Diaper
         subjects affected / exposed
    3 / 4 (75.00%)
         occurrences all number
    8
    Rash Papular
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Rash Erythematous
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Rash Macular
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Hair Colour Changes
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    3
    Rash
         subjects affected / exposed
    3 / 4 (75.00%)
         occurrences all number
    12
    Palmar-Plantar Erythrodysaesthesia Syndrome
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Macule
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Hyperhidrosis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Papule
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Swelling Face
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Skin Ulcer
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Red Man Syndrome
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Skin Hypopigmentation
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Skin Hyperpigmentation
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Skin Exfoliation
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Skin Irritation
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Musculoskeletal and connective tissue disorders
    Muscle Contracture
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Muscle Spasms
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Osteopenia
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Infections and infestations
    Catheter Site Cellulitis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Body Tinea
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Clostridium Difficile Colitis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    4
    Candidiasis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Serratia Infection
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Sepsis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Otitis Media Acute
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Otitis Media
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Oral Candidiasis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Impetigo
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Gastroenteritis
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Urinary Tract Infection Enterococcal
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    2
    Tracheitis
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2
    Viral Infection
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Metabolism and nutrition disorders
    Dehydration
         subjects affected / exposed
    1 / 4 (25.00%)
         occurrences all number
    1
    Vitamin D Deficiency
         subjects affected / exposed
    2 / 4 (50.00%)
         occurrences all number
    2

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    31 Mar 2008
    Clarified rituximab dosing for subjects smaller than average. Clarified that a central cardiologist reviews the ECG and ECHO data for consistency, while a local cardiologist reviews the ECG and ECHO data for safety and clinical management of the subject. Clarified baseline assessments for consistency with Study AGLU03707. Clarified timeline for performing plasmapheresis. Clarified that infusion-associated reactions are related only to alglucosidase alfa for the purposes of the study.
    29 Jul 2008
    Clarified that a second cycle of immunomodulatory therapy can only be administered within the first 6 months of study participation. Clarified source of biopsy sample for Western Blot analysis. Allowed enrolment at non-US sites. Clarified source of prescribing information. Added stopping rule for fatal or life-threatening reaction to plasmapheresis/plasma exchange.
    01 Oct 2009
    Removed plasmapheresis globally from the protocol as it had been determined that the frequency of administration allowed by the protocol would not be clinically meaningful for the subject population. Clarified that historical CRIM testing results were acceptable. Added details on the indication for IVIG administration. Clarified the risks associated with IVIG therapy. Added NCI/CTCAE grading to the associated severity category throughout the protocol. Expanded criteria for removing a subject from the study to include receipt of interventions or procedures that may impact the efficacy or safety of the required study assessments and treatments. Added new information on delayed onset of AEs related to rituximab administration. Clarified that subjects are fully evaluated for clinical stability and lack of acute illness prior to dosing. Clarified requirements for GAA mutation analysis. Added details on optional port-a-catheter. Clarified procedures for evaluating clinically significant changes in ECG findings and subsequent documentation of AEs.
    24 May 2010
    Allowed increased alglucosidase alfa dose frequency. Clarified processes for an enrolled subject later found to be CRIM-positive on Western Blot analysis. Clarified that an Investigator should determine exclusion criteria on a case-by-case basis. Clarified that the GMFM-88 is utilized rather than the GMFM-66.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Due to the small number of subjects assessed in this study the results must be interpreted with caution.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 19:03:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA